The effects of tamoxifen on peripheral plasma concentrations of gonadotrophins were studied in ovariectomized ewes. First 
INTRODUCTION
Treatments which interfere with the negative feedback effects of oestrogen on gonado¬ trophin secretion can lead to a stimulation of ovulation rate, offering a means of increasing fecundity in domestic animals. For example, immunization of ewes against androstenedione increases plasma luteinizing hormone (LH) concentrations and ovulation rate (Scaramuzzi, Davidson & van Look, 1977; Martensz & Scaramuzzi, 1979) .
Another approach to enhance gonadotrophin secretion would be to use a selective antioestrogen. It is thought that the oestrogen antagonist clomiphene acts in this way to stimulate folliculogenesis in women (Insler & Lunenfeld, 1976) . Attempts to use clomiphene to increase ovulation rates in sheep have not been encouraging (Land & Scaramuzzi, 1979) . The triphenylethylene tamoxifen can exhibit oestrogen agonist or antagonist activities depending on the species or the target organ (see Patterson, 1981 for references). Furthermore, it has been shown that effects can vary within tissues, between different cell types (Clark & Guthrie, 1981) . The in-vivo oestrogenic action of tamoxifen in sheep has not been reported, although it behaved as a pure oestrogen antagonist to negate the effects of oestrogen on gonadotrophin secretion by ovine pituitary cells in vitro (Miller & Huang, 1981 (Diekman & Malven, 1973; Goodman, Pickover & Karsch, 1981) .
The short-term effects of tamoxifen citrate and oestradiol benzoate (OB) on plasma gonadotrophin levels were studied in 16 ovariectomized ewes which were housed in individual pens. Polyethylene cannulae had been previously inserted into one jugular vein of each ewe and these were kept patent with 015M-NaCl (saline) containing 75 units/ml heparin. The Lee, de Kretser & Cumming (1980) . Assay standards were NIH-0LH-SI8 and NIH-0FSH-S6 (NIH, Baltimore, Maryland, U.S.A.). The assays were computed by the method Burger, Lee & Rennie (1972) . For plasma LH, assay sensitivity was 0·2µg/l and the intra-assay coefficient of variation (c.v.) at maximum precision was 5-1-7-6% between 61 and 9·4µg/l. The interassay c.v. was 8-8% at 22^g/l, 10-3% at 14-6 µ §/1 and 7-2% at 40^g/l. For plasma FSH, assay sensitivity was 10µg/l and the intra-assay c.v. at maximum precision was 5-0-9-0% between 112 and 171 µg/l. The interassay c.v. was 15-3% at 28 µg/l, 9-8% at 132 µg/l, 6-1% at 378 µ §/1 and 8-4% at 475µg/l. All (Fig. 2) (Fig. 3) , and peak values (39-84 µg/l) 24 h after injection in three sheep and 32 h after injection in the other sheep. Immediately before the OB-induced LH surges, the plasma levels of LH (4-6 + 0-9 µg/l) were significantly (P<005) lower than pretreatment levels (10 +1-6 µ §/1).
Six hours after the first injection of tamoxifen, the concentration of LH in plasma was reduced (/,<005) from 6-5+1-1 to 4-1 + 0-4µ£/1 ( = 8; tamoxifen and tamoxifen + OB groups). In sheep given tamoxifen alone there was no evidence of an LH surge (Fig. 3 ).
After treatment with both tamoxifen and OB, two out of four ovariectomized ewes showed LH surges of comparable magnitude (91 and 94µg/l respectively) to those seen in OBtreated ovariectomized ewes with peak values occurring 22 h after the OB (Fig. 3) . Plasma LH concentrations were not affected in the control ewes (Fig. 3) .
Treatment of ovariectomized ewes with OB caused a gradual reduction in the plasma FSH concentration and the value 8 h after injection (392 + 55µg/l) was significantly (/><0-05) lower than the preinjection value (445+47µg/l) (Fig. 4) . Treatment with tamoxifen caused a significant (P<005) reduction in the plasma FSH concentration within 6 h of the first injection, the value falling from 275 + 5 to 233 + 16 µ£/1; thereafter a further downward trend was apparent (Fig. 4) Miller & Huang (1981) where no agonist action was shown. This difference may be due, in part, to in-vivo metabolism of tamoxifen, which is readily converted to mono-and dihydroxylated forms (Fromson, Pearson & Bramah, 1973) . Monohydroxylated tamoxifen is the major metabolite and has more oestrogenic activity in the rat uterus than its parent compound (Jordan, 1976; Jordan & Prestwich, 1977) . If tamoxifen was hydroxylated after injection into ovariectomized ewes but was not hydroxylated in cell culture medium, this could explain why the in-vivo results suggest only agonist activity whereas the in-vitro studies (Miller & Huang, 1981) do not.
The reduced plasma FSH concentrations in ovariectomized ewes that were apparent 2 weeks after tamoxifen treatment in experiment 1 could have been a residual effect. Tamoxifen is known to have a long half-life (Adam, Patterson & Kemp, 1980 (Diekman & Malven, 1973; Goodman et al. 1981 (Radford, Wheatley & Wallace, 1969; Scaramuzzi, Tillson, Thorneycroft & Caldwell, 1971) . Even very weak oestrogens, like the catecholoestrogens, have this effect (Clarke, Wynne, Funder & Findlay, 1982 (Peet & Lincoln, 1977; Clarke & Doughton, 1983) and to prevent the LH surge (Radford & Wallace, 1974; Jackson, 1975) . The overall inhibitory effect of tamoxifen on gonadotrophin secretion, without the biphasic response characteristic of oestrogens (see above), could be explained in this way. Any central effects would be superimposed on effects at the pituitary level which would most likely be mediated via oestrogen receptors since there are no direct neural inputs to the pars distalis. It is possible that any non-oestrogen receptor mediated effects of tamoxifen involve 'specific' binding sites for antioestrogen which have been described (Sutherland, Murphy, San Foo, Green, Whybourne & Krozowski, 1980 
